Celon Pharma S.A. Integrated pharma innovation
An integrated Polish pharmaceutical company that conducts advanced research, manufactures modern drugs, and holds marketing authorisations for its own products with an R&D team of more than 160 scientists targeting oncology, neurology, diabetes, and metabolic-disease therapeutics.
Celon Pharma S.A. Investor Relations Video Hub
All CEO & CFO video presentations from Celon Pharma S.A. filter by format below to find what you need.
Celon Pharma S.A. Company Presentation | Pioneering Pharmaceutical Innovation
Join CEO Maciej Wieczorek as he unveils the cutting-edge research and life-changing drug developments of Celon Pharma S.A., a stock-listed pharmaceutical company dedicated to improving patients' lives.
Watch presentation
Integrated pharma innovation
Celon Pharma S.A. is an integrated Polish pharmaceutical company that conducts advanced research, manufactures modern drugs, and is a successful marketing-authorisation holder for its own products. The drugs the Group offers help thousands of patients lead better and longer lives combining a commercial generics and branded-drug portfolio with a deeper innovation pipeline.
Robust R&D Facilities
One of Celon Pharma's principal advantages is its strong research and development infrastructure, which allows the company to develop entirely new classes of effective drugs. The R&D centre is purpose-built to host preclinical and clinical-stage programmes, supporting both small-molecule chemistry and biologics research.
Expertise in the R&D Team
Celon Pharma's research and development department employs over 160 scientists, of whom approximately one in four hold PhD titles in molecular biology, pharmacy, or chemistry. This depth of scientific talent underpins the Group's ability to advance multiple innovative programmes in parallel, from target discovery through to first-in-human studies.
Investment in Innovative Pharmaceutical Products
The Group invests in the development of innovative pharmaceutical products with the potential to treat cancers, neurological diseases, diabetes, and other metabolic disorders. This diversified pipeline positions Celon Pharma to capture value across several large therapeutic areas, balancing nearer-term commercial assets with longer-dated R&D opportunities.
Want your company
on seat11a?
Join Celon Pharma and 100+ listed companies reaching institutional investors through CEO and CFO video presentations.